Malenti Strings: Intrapreneurship within FLG, Inc.Case Solution
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
PUBLICATION DATE: October 11, 2016
The case informs the story of Synthroid from its advancement in 1958 as the very first artificial thyroxine particle to its competitors versus common substitutes in 2004. Due to the fact that Synthroid was established and presented prior to FDA guidelines and drug requirements of identity were totally developed, it was challenging for rivals to get their drugs accredited as similar to Synthroid. Through a series of initiatives with doctors, specifically endocrinologists, Synthroid's owners were capable to keep the understanding for forty-six years that Synthroid was distinctively efficient. Trainees are challenged to think about choices to preserve the drug's system volume, earnings, and/or revenue in these challenging scenarios. The (A) case offers overview on the history of the drug, the pharmaceutical market and its advertising methods, and hypothyroidism and its procedure, and it concludes in 2004 as Abbott's online marketers deal with the approaching difficulty of safeguarding the Synthroid service versus generic competitors.
Related Case Solutions & Analyses:
New Approach to Fix Broken Governance
Ericsson: Leading in Times of Change
Carvajal, S.A.: Building on a Century of Business Growth and Family Values
Measured Approach: TEGV Assesses its Performance & Impact on Educational Enrichment Programs
Three Trends That Will Change How You Manage: Globalization, Digitization and Politicization
Growth Hacking at Bazaart (A)
Risk Control Strategies: Human Resource Challenges
Social Media Revolutions: The Influence of Secondary Stakeholders
Zensar: The Future of Vision Communities (A)
An Inspired Model… or a Misguided One? Oprah Winfrey’s Dream School for Impoverished South African Girls
